drug · antibody
patient view →ustekinumab
Marketedupdated 2mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $10.4B
community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 27 investigational indications.
indications
investigational
IBD (Crohn's + UC)
targets
Interleukin-12Interleukin-23
all catalysts(14)
approval · 14
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that